BG
PCRX icon

BlackRock Group’s Pacira BioSciences PCRX Stock Holding History

BlackRock Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1.83M Sell
56,709
-53,507
-49% -$1.79M ﹤0.01% 1826
2016
Q3 		$3.77M Buy
110,216
+87,372
+382% +$3.42M ﹤0.01% 1246
2016
Q2 		$771K Sell
22,844
-210
-0.9% -$10.3K ﹤0.01% 2084
2016
Q1 		$1.22M Buy
23,054
+3,472
+18% +$203K ﹤0.01% 1834
2015
Q4 		$1.5M Buy
19,582
+586
+3% +$33.2K ﹤0.01% 1645
2015
Q3 		$780K Buy
18,996
+5,003
+36% +$306K ﹤0.01% 2018
2015
Q2 		$990K Sell
13,993
-571
-4% -$45K ﹤0.01% 1966
2015
Q1 		$1.29M Buy
14,564
+5,297
+57% +$537K ﹤0.01% 1727
2014
Q4 		$821K Sell
9,267
-27,440
-75% -$2.6M ﹤0.01% 2003
2014
Q3 		$3.56M Buy
36,707
+30,576
+499% +$2.97M ﹤0.01% 1202
2014
Q2 		$564K Sell
6,131
-10,893
-64% -$829K ﹤0.01% 2156
2014
Q1 		$1.19M Buy
17,024
+6,230
+58% +$424K ﹤0.01% 1906
2013
Q4 		$620K Buy
10,794
+4,625
+75% +$243K ﹤0.01% 2152
2013
Q3 		$297K Buy
6,169
+4,365
+242% +$159K ﹤0.01% 2382
2013
Q2 		$52K Buy
+1,804
New +$52.2K ﹤0.01% 2434

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BlackRock Group's PCRX Position: Q4 2016 in Review

BlackRock Group reduced its Pacira BioSciences (PCRX) stake by 49% in Q4 2016, selling an estimated $1.79M and leaving 56,709 shares worth $1.83M. The position accounts for ﹤0.01% of the portfolio, ranked #1826.

BlackRock Group first reported a position in PCRX in Q2 2013 and has held it in 15 quarters since. The position peaked at $3.77M in Q3 2016. 182 funds tracked by Wall St. Rank hold PCRX as of Q4 2016.

  • BlackRock Group held 56,709 shares of Pacira BioSciences worth $1.83M as of Q4 2016.
  • BlackRock Group sold 53,507 Pacira BioSciences shares in Q4 2016, an estimated $1.79M.
  • Pacira BioSciences made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #1826 holding.
  • BlackRock Group first reported a position in Pacira BioSciences in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Group's Pacira BioSciences position peaked at $3.77M in Q3 2016.
  • 182 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.